Corporate Governance Corporate Governance Overview How our governance supports the delivery of our strategy.
Board Audit Committee Remuneration Committee Chairman: Leif Johansson Chairman: Rudy Markham Chairman: Graham Chipchase 6HQLRU LQGHSHQGHQW 1RQ [HFXWLYH 'LUHFWRU 5XG 0DUNKDP The Audit Committee provides The Remuneration Committee assurance to the Board in the considers and sets, on behalf All Directors are collectively responsible for the success of the Group.
following areas: the integrity RIbWKH %RDUG WKH UHPXQHUDWLRQ 7KHb1RQ [HFXWLYH 'LUHFWRUV H[HUFLVH LQGHSHQGHQW REMHFWLYH MXGJHPHQW RIbRXU QDQFLDO UHSRUWLQJ DQG including pension rights and LQbUHVSHFW RI %RDUG GHFLVLRQV DQG VFUXWLQLVH DQG FKDOOHQJH PDQDJHPHQW LQWHUQDO FRQWUROV RYHU QDQFLDO compensation payments of They also have various responsibilities concerning the integrity of matters: our internal controls over Executive Directors and other QDQFLDO LQIRUPDWLRQ LQWHUQDO FRQWUROV DQG ULVN PDQDJHPHQW QRQ QDQFLDO PDWWHUV FRPSOLDQFH senior executives.
No Director The Board is responsible for setting our strategy and policies, overseeing with laws and our Code of LVbLQYROYHG LQ GHFLGLQJ KLV RU KHU risk and corporate governance, and monitoring progress towards meeting Conduct: the quality of the own remuneration.
our objectives and annual plans.
It is accountable to our shareholders for Companys relationship with the proper conduct of the business and our long-term success, and LWVbH[WHUQDO DXGLWRU WKH UROH represents the interests of all stakeholders.
UHVRXUFHV DQG HHFWLYHQHVV RI WKHb&RPSDQ V LQWHUQDO DXGLW The Board conducts an annual review of the Groups overall strategy.
The CEO, CFO and Senior Executive Team SET take the lead in IXQFWLRQ DQG WKH HHFWLYHQHVV RI the Companys risk management developing our strategy, which is then reviewed, constructively challenged and approved by the Board.
framework, in each case with the ultimate aim of protecting our The Board has delegated some of its powers to the CEO and operates with shareholders interests.
the assistance of four Committees.
Members of the Board and their biographies are shown on pages 86 and 87.
Corporate Governance Report from page 90 Audit Committee Report from Directors Remuneration page 98 Report from page 103 Board Committee membership and meeting attendance in 2016 Nomination and 1 Name Board Audit Remuneration Governance Science Independent Cori Bargmann 8 9 3 3 Genevive Berger 11 11 4 4 Bruce Burlington 10 11 5 5 4 4 Chairman 4 4 Ann Cairns 8 11 4 5 Graham Chipchase 11 11 Chairman 5 5 4 4 Jean-Philippe Courtois 8 10 4 4 Marc Dunoyer 11 11 N A 4 Leif Johansson Chairman 11 11 4 5 Chairman 4 4 N A Rudy Markham 11 11 Chairman 5 5 4 5 4 4 Pascal Soriot 11 11 N A Shriti Vadera 11 11 5 5 5 5 Marcus Wallenberg 9 11 4 4 Note: number in brackets denotes number of meetings during the year that Board members were entitled to attend.
1 As determined by the Board for the purposes of the UK Corporate Governance Code.
2 &RUL %DUJPDQQ VWHSSHG GRZQ IURP WKH %RDUG DQG DV D PHPEHU RI WKH 6FLHQFH &RPPLWWHH ZLWK HHFW IURP 2FWREHU 3 -HDQ 3KLOLSSH &RXUWRLV VWHSSHG GRZQ IURP WKH %RDUG DQG DV D PHPEHU RI WKH $XGLW &RPPLWWHH ZLWK HHFW IURP 'HFHPEHU 4 Leif Johansson was considered by the Board to be independent upon his appointment as Chairman.
In accordance with the UK Corporate Governance Code, the test of independence is not appropriate in relation to the Chairman after his appointment.
84 AstraZeneca Annual Report and Form 20-F Information 2016 Corporate Governance Nomination and Science Committee Senior Executive Team Key governance roles Governance Committee Chairman: Chairman: Leif Johansson Chairman: Bruce Burlington The members of the SET are: Leadership, operation and governance of the Board, ensuring The Nomination and Governance The Science Committee provides CEO %RDUG HHFWLYHQHVV Committee recommends new assurance to the Board regarding CFO Board appointments for decision the Groups R&D activities !
1LQH [HFXWLYH 9LFH CEO: by the Board and, more broadly, by reviewing and assessing Presidents EVPs from across Responsible to the Board for the considers succession planning for our approaches in our chosen the organisation, representing management, development and senior executive management and WKHUDS DUHDV WKH VFLHQWLF the three science units, the performance of the business Board positions.
The Nomination technology and R&D capabilities YH FRPPHUFLDO XQLWV Senior independent and Governance Committee also we deploy: the quality and including GPPS, Operations 1RQ [HFXWLYH 'LUHFWRU DGYLVHV WKH %RDUG RQ VLJQLFDQW GHYHORSPHQW RI RXUbVFLHQWLVWV & IT and HR Acts as a sounding board for the developments in corporate and our decision making.
General Counsel Chairman and an intermediary for governance.
&KLHI &RPSOLDQFH 2FHU other Directors and shareholders when necessary The SET is the body through which the CEO exercises the authority delegated to him by the Board.
It usually meets monthly and considers major business issues and makes recommendations to the CEO, and typically reviews matters that are to be submitted to the Board for its consideration.
The CEO is responsible for establishing and chairing the SET.
Nomination and Governance Science Committee from The biographies of SET Committee from page 93 page 93 members are shown on pages 88 and 89 Length of tenure of Gender split of Non-Executive Directors Directors as at 31 December 2016 Male 7 Under 3 years 1 Ann Cairns Female 3 36 years 4 Leif Johansson Genevive Berger Graham Chipchase Shriti Vadera 69 years 2 Directors Bruce Burlington nationalities as at Rudy Markham 31 December 2016 9 years 1 Marcus Wallenberg American 1 British 4 French 3 Swedish 2 AstraZeneca Annual Report and Form 20-F Information 2016 85
